Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;6(1):67-89.
doi: 10.1016/j.iccl.2016.08.006.

Switching P2Y12 Receptor Inhibiting Therapies

Fabiana Rollini  1 , Francesco Franchi  2 , Dominick J Angiolillo  2
Affiliations
Review

Switching P2Y12 Receptor Inhibiting Therapies

Fabiana Rollini et al. Interv Cardiol Clin. 2017 Jan.

Abstract

Antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor is the cornerstone of treatment of patients with atherothrombotic disease manifestations. Switching between P2Y12 inhibitors occurs commonly in clinical practice for a variety of reasons, including safety, efficacy, adherence, and economic considerations. There are concerns about the optimal approach for switching because of potential drug interactions, which may lead to ineffective platelet inhibition and thrombotic complications, or potential overdosing due to overlap in drug therapy, which might cause excessive platelet inhibition and increased bleeding. This review provides practical considerations of switching based on pharmacodynamic and clinical data available from the literature.

Keywords: Cangrelor; Clopidogrel; P2Y(12) receptor inhibitors; Prasugrel; Switching; Ticagrelor.

PubMed Disclaimer

MeSH terms

Substances

LinkOut - more resources